Clinical Research Directory
Browse clinical research sites, groups, and studies.
The Cancer of the Pancreas Screening-5 CAPS5)Study
Sponsor: Johns Hopkins University
Summary
Johns Hopkins clinical research office quality assurance group will monitor and audit this study at Johns Hopkins. The Sub Investigator at each site will be responsible for internal monitoring at their site.
Key Details
Gender
All
Age Range
18 Years - Any
Study Type
INTERVENTIONAL
Enrollment
9000
Start Date
2014-01-06
Completion Date
2029-06
Last Updated
2025-10-09
Healthy Volunteers
No
Conditions
Interventions
Secretin
inject Secretin to stimulate pancreatic digestive fluid, which is collected in duodenum near ampulla via endoscope suction port. This fluid will be assessed for biomarkers.
MRI
MRI abdomen with contrast (MRCP) will be clinically indicated for abnormal novel CA-19-9 lab results.
Tumor marker gene test with CA19-9
A tumor marker gene test that will be used to stratify individuals into one of several circulating tumor marker reference ranges for CA19-9. The variants in the genes FUT3 and FUT2 affect the levels of CA19-9.
Locations (9)
Yale University
New Haven, Connecticut, United States
Johns Hopkins Hospital
Baltimore, Maryland, United States
Dana Farber Cancer Center, Harvard University
Boston, Massachusetts, United States
University of Michigan
Ann Arbor, Michigan, United States
NYU Langone Medical Center
New York, New York, United States
Columbia University Medical Center
New York, New York, United States
Case Comprehensive Cancer Center, Case Western Medical Reserve
Cleveland, Ohio, United States
University of Pennsylvania
Philadelphia, Pennsylvania, United States
University of Pittsburgh
Pittsburgh, Pennsylvania, United States